This website uses cookies to improve the user experience. If you continue on this website, you will provide your consent to our use of cookies.

Access Contact 日本語
  1. TOP
  2. Research grants
  3. Hidenori Ando

Hidenori Ando Hidenori Ando

Associate Professor, Graduate School of Biomedical Sciences, Tokushima University *Profile is at the time of the award.

2026AccelerateScience & Engineering

researchmap
Research topics
Innovative antibody drug discovery targeting membrane proteins for the treatment of malignant lymphoma
Keyword
Summary
We have previously developed a spleen-targeting immunization strategy that enables the direct delivery of membrane protein antigens to the spleen using carrier systems such as liposomes. By leveraging this approach, we have successfully induced antibodies that recognize membrane proteins that express on the cellular membrane. Notably, this platform has enabled the generation of antibodies against multi-pass transmembrane proteins, including G protein–coupled receptors (GPCRs), which have traditionally been considered challenging targets for antibody induction. These findings highlight the substantial potential of spleen-targeting immunization as a practical and versatile antibody discovery platform. In this study, we aim to generate novel monoclonal antibodies against membrane protein targets for the treatment of refractory malignant lymphoma.

Message

This study aims to realize innovative antibody-based therapeutics for malignant lymphoma by building upon our previously developed spleen-targeted drug delivery system (DDS) and its derivative technology for the efficient induction of antibodies against membrane proteins. As a key outcome of this project, we generate monoclonal antibodies targeting novel membrane protein antigens expressed on lymphoma cells. In the future, these antibodies will be further developed into advanced therapeutic modalities, including antibody–drug conjugates (ADCs) and antibody-functionalized nanoparticles. Through these efforts, I strongly expect to establish a new technological paradigm for the treatment of malignant lymphoma.

Find other recipients

Science & Engineering(takameru)

PAGE TOP